Geodesic distance on a Grassmannian for monitoring the progression of Alzheimer's disease
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative brain disorder that is mainly characterized by both memory loss and cognitive decline and which usually succeeds from mild cognitive impairment (MCI). MCI is considered as an intermediary stage between normal aging and dementia. Patients who have reached this MCI stage are known to incur a very high risk of progressing to probable AD (Morris et al., 2001). From observations of this progression, we know that the medial temporal lobe (MTL) structures of the human brain, including the hippocampus, the amygdala, and the entorhinal cortex, are affected the earliest and the most severely in the neuropathology of AD (Hyman et al., 1984), exhibiting significant degrees of atrophy that occur at elevated rates in both MCI and AD compared to those induced by normal aging (Du et al., 2001, Jack et al., 1997, Krasuski et al., 1998, Laakso et al., 1995). Due to the spatial adjacency of the lateral ventricle (LV) to those MTL structures, LV enlargement is a consistent observation across a variety of AD studies (Chetelat and Baron, 2003, McKhann et al., 1984, Ridha et al., 2008). Such an exploration of the MTL structures and the LV in the neuropathology of AD has largely been facilitated by the advent of modern magnetic resonance imaging (MRI) techniques.
With the development of specialized, geometry-based, mathematical tools that can be utilized in the analysis of MRI, in conjunction with traditional volumetric analysis, shape analyses of MTL structures and of the LV have gained substantial popularity in the investigation of AD, with a large number of innovative results being obtained by multiple research groups (Apostolova et al., 2006, Csernansky et al., 2005, Frisoni et al., 2008, Miller et al., 2015, Qiu et al., 2009, Scher et al., 2007, Tang et al., 2014, Tang et al., 2015a, Tang et al., 2015b, Tang et al., 2015c, Thompson et al., 2004). In contrast to the volumetric measurement, shape morphometrics can not only quantify brain tissue loss but also characterize more detailed localized morphometric abnormality patterns.
The general approach in shape analysis is to identify a localized morphometric quantity (a scalar or a vector at each vertex of the structural surface of interest), such as the vertex-wise surface area and the vertex-wise deformation factor, and to perform statistical analyses (cross-sectional or longitudinal) on that vertex-based quantity. An alternative approach is to identify a metric (distance) between two shapes upon which statistical analyses, such as cross-sectional group comparisons, disease-versus-normal classifications, and regressions, can then be conducted. A variety of shape metrics have been proposed and applied in brain morphometry analyses, such as the diffeomorphic metric distance in the setting of large deformation diffeomorphic metric mapping (Ceyhan et al., 2012, Feng et al., 2013, Miller et al., 2002, Yang et al., 2012) and the Wasserstein Distance (Su et al., 2015).
Over the past few decades, researchers have actively pursued the modeling of shapes that are invariant under a given type of transformation by building a shape space (Bryner et al., 2014; Dryden, 1998; Fletcher et al., 2009; Jayasumana et al., 2013; Kendall, 1984; Le and Kendall, 1993; Lele and Richtsmeier, 2001; Pennec et al., 2006; Small, 1996; Swann and Olsen, 2003; Younes, 2012). A space formed from shapes that are invariant under such a carefully-defined group of transformations has the underlying geometrical structure of a manifold. For example, when considering affine transformations, the shape space is a Grassmannian manifold and a shape thus becomes a point on this Grassmannian manifold (Begelfor and Werman, 2006, Patrangenaru and Mardia, 2003, Sepiashvili et al., 2003, Srivastava et al., 2005, Turaga et al., 2011). In fact, in our approach, we will focus on shapes distorted by affine transformations, since affine transformations well approximate the general projective transformations, and we will study the shape space in the framework of Grassmannian manifolds. For any individual MRI scan, we can represent any one of its anatomical regions of interest (ROIs), such as the left hippocampus, with a set of landmarks. We refer to these landmarks as the configuration of that anatomical ROI. This configuration may change when the MRI scans are taken from different viewpoints. In longitudinal studies, for it to be feasible to compare different scans of the same individual, we must factor out the distortions within the configurations of the anatomical ROI induced by the particular viewpoint from which that MRI scan was acquired. We model these distortions with affine transformations that may account for, say, rotation, stretching, scaling, or other effects. As such, the affine-invariant geometric structure extracted from the configuration of an anatomical ROI in an MRI scan is defined as the shape of that ROI. By making this identification, we have guaranteed that the shape remains the same regardless of viewpoint. We recall that the shape, as a point on the Grassmannian, is a vector space. In fact, under this definition, the shape of a specific anatomical ROI can be represented as a 3-dimensional linear subspace in , and thus a point on the Grassmannian . To compare the shapes of a specific ROI across longitudinal time points, we need to introduce a measure of similarity (or dissimilarity). If we were comparing the shapes in the standard Euclidean space , then a reasonable similarity measure would be the Euclidean distance between the landmark sets configuring different scans. Given that the shapes representing different longitudinal scans are now points on the Grassmannian, we adopt, as the distance between two shapes, the distance between the two points on our Grassmannian manifold. A variety of such metrics exist, such as the Procrustes distance (Turaga et al., 2011), the Projection metric (Edelman et al., 1998), and the Binet-Cauchy metric (Wolf and Shashua, 2003). In this work, we adopt a geodesic-based distance (Gui et al., 2016) and explore its practical application to the comparison of ROI shapes across longitudinal time points. We will demonstrate the applicability of this geodesic distance as a similarity (or dissimilarity) measure in the analysis of structural shape variation over time and the relative impact of disease states upon the patterns thereof.
In summary, we investigate the use of a geodesic distance defined on the Grassmannian manifold to study, both longitudinally and cross-sectionally, the shape of the hippocampus, the amygdala, and the LV in both hemispheres along with its relevance to the progression of AD. The primary goal of this paper is to quantitatively assess whether or not the rates of change in this geodesic distance vary significantly as a function of disease severity during the progression towards AD. In addition to these cross-sectional comparisons, we also examine the potential of using this geodesic distance on the Grassmannian as a surrogate biomarker of AD. A biomarker would not be useful in clinical applications if it could not be significantly linked with cognitive declines (Black, 1999). Therefore, we statistically quantify how the changes in this geodesic distance between shapes of a structure of interest link with changes in cognitive measures.
We utilize two of the most prominent cognitive measures in the study of AD, the Alzheimer’s Disease Assessment Scale-Cognitive Behavior Section (ADAS-cog) (Rosen et al., 1984) and the Mini Mental State Examination (MMSE) (Folstein et al., 1975). ADAS-cog measures a number of cognitive domains, including components of memory, language, and praxis; it is scored from 0–70 with higher values indicating greater cognitive impairment. MMSE provides a continuous scale to assess primary cognitive functions that are affected by the dementia of the Alzheimer type, including orientation, registration, attention, recall, language and constructional praxis. The MMSE score ranges from 0–30 and, in contrast to ADAS-cog, lower MMSE scores indicate more severe cognitive impairment.
In this study, we use data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) study, including a total of 210 healthy control (HC) subjects, 369 MCI subjects, and 175 AD subjects at baseline, each with a sequential MRI dataset obtained over 6- or 12-month intervals within a follow-up period of 6–36 months, resulting in a total of 3092 scans included in the analysis. From this data we aim to extract the following results: (1) the mean and standard deviations of the geodesic distance, for the shape of each of the six structures of interest (left and right hippocampus, amygdala, and lateral ventricle), between the baseline shape and that of each follow-up scan as computed across the subjects of each of the three clinical groups, allowing direct longitudinal and cross-sectional comparisons; (2) the outcome of group comparisons, in terms of each structure’s rate of change in the geodesic distance, between HC and MCI as well as HC and AD via a linear mixed-effects statistical model; (3) the annualized rates of change in the geodesic distance for each structure of interest, in each of the three groups, as estimated from the linear mixed-effects model after removing co-variate effects; (4) the statistical associations (in terms of both strength and significance) between the geodesic distance and changes in the two AD-related cognitive measure (ADAS-cog and MMSE) within 6 months, 12 months, 18 months, 24 months, and 36 months from the baseline for each of the six structures of interest within the whole group (all three cohorts combined). We also quantitatively evaluate the computational efficiency of obtaining this geodesic distance as a potential surrogate biomarker for AD.
Section snippets
Alzheimer's Disease Neuroimaging Initiative
Data used in preparation of this manuscript were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, the Food and Drug Administration, private pharmaceutical companies and non-profit organizations, as a $60 million, 5-year public-and-private partnership. The primary goal of ADNI has been to test whether serial MR
Results
For each structure of interest, we computed the geodesic distance between the baseline and each follow-up visit of each individual. We started with two configurations, for the baseline scan and for the appropriate follow-up scan of the same individual (as demonstrated in Eq. (1)), and then obtained the matrix representations of their shapes with Eq. (2) and Eq. (3), and finally calculated the geodesic distance between them with Eq. (4). All computations were conducted on an Intel Core
Discussion
In this paper, we proposed a geodesic distance between points on a Grassmannian manifold, with each point representing the shape configuration of an anatomical structure of interest (e.g. the left hippocampus as extracted from an MRI scan). We used that geodesic distance, as a similarity (or dissimilarity) measure, to quantify the shape progression patterns of the hippocampus, the amygdala, and the lateral ventricle in normal aging, mild cognitive impairment, and Alzheimer's disease.
Conclusions
We designed a novel geodesic distance on a Grassmannian manifold and applied it to quantify and monitor the progression patterns, both longitudinally and cross-sectionally, of the hippocampal, amygdalar, and ventricular shapes, in normal aging, MCI, and AD. The proposed geodesic distance is a simple, computationally-friendly, and powerful single statistic that not only characterizes the global change in shape but also tightly links to the neurodegenerations of Alzheimer's disease. This distance
Acknowledgment
This study was supported by the National Natural Science Foundation of China (NSFC 81501546) and the SYSU-CMU Shunde International Joint Research Institute Start-up Grant (20150306).
Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions
References (66)
- et al.
A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume
Neuroimage
(2004) - et al.
Quasi-conformal statistical shape analysis of hippocampal surfaces for Alzheimer׳s disease analysis
Neurocomputing
(2016) - et al.
Early diagnosis of Alzheimer’s disease: contribution of structural neuroimaging
Neuroimage
(2003) - et al.
Measurements of medial temporal lobe atrophy for prediction of Alzheimer’s disease in subjects with mild cognitive impairment
Neurobiol. Aging
(2013) - et al.
Preclinical detection of Alzheimer’s disease: hippocampal shape and volume predict dementia onset in the elderly
Neuroimage
(2005) - et al.
Prediction of Alzheimer’s disease in subjects with mild cognitive impairment from the ADNI cohort using patterns of cortical thinning
Neuroimage
(2013) - et al.
Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain
Neuron
(2002) - et al.
“Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician
J. Psychiatr. Res.
(1975) - et al.
Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data
Neuroimage
(2006) - et al.
Volumes of medial temporal lobe structures in patients with Alzheimer's disease and mild cognitive impairment (and in healthy controls)
Biol. Psychiatry
(1998)
Alzheimer’s Disease Neuroimaging Initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition
Neuroimage
The diffeomorphometry of temporal lobe structures in preclinical Alzheimer’s disease
Neuroimage Clin.
Regional shape abnormalities in mild cognitive impairment and Alzheimer’s disease
Neuroimage
Hippocampal shape analysis in Alzheimer's disease: a population-based study
Neuroimage
Detecting global and local hippocampal shape changes in Alzheimer’s disease using statistical shape models
NeuroImage
Brain development and aging: overlapping and unique patterns of change
Neuroimage
Mapping hippocampal and ventricular change in Alzheimer disease
Neuroimage
Spaces and manifolds of shapes in computer vision: an overview
Image Vis. Comput.
Inferring changepoint times of medial temporal lobe morphometric change in preclinical Alzheimer’s disease
Neuroimage Clin.
3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer’s disease
Brain
Hippocampal atrophy and ventricular enlargement in normal aging, mild cognitive impairment and Alzheimer’s disease
Alzheimer Dis. Assoc. Disord.
The search for diagnostic and progression markers in AD: so near but still too far?
Neurology
2D affine and projective shape analysis
IEEE Trans. Pattern Anal. Mach. Intell.
Metric distances between hippocampal shapes indicate different rates of change over time in nondemented and demented subjects
Curr. Alzheimer Res.
Longitudinal pattern of regional brain volume change differentiates normal aging from MCI
Neurology
Statistical shape analysis
Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer’s disease
J. Neurol. Neurosurg. Psychiatry
The geometry of algorithms with orthogonality constraints
SIAM J. Matrix Anal. Appl.
The geometric median on Riemannian manifolds with application to robust atlas estimation
NeuroImage
Cited by (7)
A survey on machine and statistical learning for longitudinal analysis of neuroimaging data in Alzheimer's disease
2020, Computer Methods and Programs in BiomedicineCitation Excerpt :Current research shows longitudinal changes in shape in key structures of the brain (such as lateral ventricles or hippocampus) that are strongly related to cognitive degeneration [73,74] and can reveal differences between groups of patients [75–77]. Mixed effect models are often used for modelling shape changes [73–76], with [46] proposing a novel vertex clustering method to model shape changes over time, using a similar mixed effect model already proposed in other reviewed works [71,82,114]. Besides the methods discussed so far, other types of models for disease progression are also used.
Longitudinal assessment of quantitative ultra-widefield ischaemic and vascular parameters in sickle cell retinopathy
2022, British Journal of OphthalmologyUtilizing average symmetrical surface distance in active shape modeling for subcortical surface generation with slow-fast learning
2022, Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, EMBS